OTCPK:SCAL

Stock Analysis Report

Executive Summary

Stem Cell Authority, Ltd., a technology development company, focuses on the collection and cryogenic preservation of stem cells.

Snowflake

Fundamentals

Adequate balance sheet with weak fundamentals.

Risks

  • Stem Cell Authority's last earnings update was 3534 days ago.
  • Stem Cell Authority is not covered by any analysts.

Share Price & News

How has Stem Cell Authority's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

OTCPK:SCAL

0.6%

US Healthcare

1.1%

US Market


1 Year Return

-50.0%

OTCPK:SCAL

-7.7%

US Healthcare

2.1%

US Market

SCAL underperformed the Healthcare industry which returned -4% over the past year.

SCAL underperformed the Market in United States of America which returned -0.1% over the past year.


Share holder returns

SCALIndustryMarket
7 Day0%0.6%1.1%
30 Day0%-0.9%3.7%
90 Dayn/a0.02%2.3%
1 Year-50.0%-50.0%-6.3%-7.7%4.4%2.1%
3 Year-90.0%-90.0%31.5%26.2%47.0%37.4%
5 Year-98.9%-98.9%65.6%55.8%61.6%43.8%

Price Volatility Vs. Market

How volatile is Stem Cell Authority's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Stem Cell Authority undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether Stem Cell Authority is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Stem Cell Authority has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Examine Stem Cell Authority's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Stem Cell Authority regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Stem Cell Authority expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

10.9%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Stem Cell Authority has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Stem Cell Authority performed over the past 5 years?

0.1%

Historical Healthcare annual earnings growth


In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Stem Cell Authority has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Next Steps

Financial Health

How is Stem Cell Authority's financial position?


In this section we usually analyse Stem Cell Authority's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Stem Cell Authority has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of SCAL’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Stem Cell Authority's financial data was last updated here.
  • Explore more healthy companies in the Healthcare industry.

Dividend

What is Stem Cell Authority's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Stem Cell Authority's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Stem Cell Authority's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Stem Cell Authority has not reported any payouts.

Unable to verify if Stem Cell Authority's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Stem Cell Authority has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Stem Cell Authority's salary, the management and board of directors tenure and is there insider trading?


CEO

Carlzo Cardwell 0

0yrs

Tenure

0

Mr. Carlzo Bernard Cardwell is the Founder, Chief Executive Officer and President of Stem Cell Authority, Ltd. (Formerly Five Nines Ltd) and served as its Chairman and Director since May 2005. Mr. Cardwell ...


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Carlzo Cardwell

    Founder

    • Tenure: 0yrs

Board Members

    Company Information

    Stem Cell Authority, Ltd.'s company bio, employee growth, exchange listings and data sources


    Key Information

    • Name: Stem Cell Authority, Ltd.
    • Ticker: SCAL
    • Exchange: OTCPK
    • Founded:
    • Industry: Health Care Services
    • Sector: Healthcare
    • Market Cap: US$34.870k
    • Shares outstanding: 348.71m
    • Website: https://www.stemcellauthority.com

    Location

    • Stem Cell Authority, Ltd.
    • 123 South Miller Road
    • Fairlawn
    • Ohio
    • 44333
    • United States

    Listings

    TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
    SCALOTCPK (Pink Sheets LLC)YesCommon StockUSUSDJan 2005

    Biography

    Stem Cell Authority, Ltd., a technology development company, focuses on the collection and cryogenic preservation of stem cells. It specializes in the collection and cryogenic preservation of the hematopoi ...


    Company Analysis and Financial Data Status

    All financial data provided by Standard & Poor's Capital IQ.
    DataLast Updated (UTC time)
    Company Analysis2019/08/13 23:59
    End of Day Share Price2019/05/16 00:00
    Earnings2009/08/31
    Annual Earnings2009/08/31


    Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.